Novo Holdings, a leading international life sciences investor, announces that its portfolio company NMD Pharma, a clinical stage biotech company developing first-in-class, small molecule ClC-1 inhibitors for neuromuscular disorders, reported positive top-line results from a Phase I/IIa clinical trial for its lead .
Data provide first clinical proof of mechanism of action and clinical utility of NMD Pharma's lead asset NMD670 in Myasthenia GravisThe clinical validation provides a unique translational
Novo Holdings Portfolio Company Syndesi Therapeutics acquired by AbbVie· Deal value of US$ 1 billion with US$ 130 million upfront· Novo Holdings co-created Syndesi Therapeutics in partnership with UCB Pharma and co-led the Series A financing&m.
/PRNewswire/ Novo Holdings, a leading international life sciences investor, today announces that its portfolio company Syndesi Therapeutics ( Syndesi ) has.